ランキング価格はじめての方へ
  1. 米国企業
  2. Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.XERS

時価総額
$4億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2021年
12月31日		2022年
12月31日		2023年
6月30日
Net loss-123-95-37
Depreciation and amortization111
Amortization of Intangible Assets1115
Amortization of investments-0-01
Amortization of debt issuance costs121
Amortization of operating right-of-use assets-00
Deferred income tax benefit--1-
Stock-based compensation11125
Loss on extinguishment of debt--1-
Loss on disposal of property and equipment--0-
Gain on the remeasurement of lease liabilities-1-
Change in fair value of warrants-2-0
Change in fair value of contingent value rights-3-2
Trade accounts receivable613-1
Increase (Decrease) in Prepaid Expense-34-1
Inventory7711
Accounts payable6-47
Other accrued liabilities13-11-11
Accrued trade discounts and rebates42-
Accrued returns reserve170
Supply agreement liabilities--5-7
Operating lease liabilities--16
Other-131
Net cash used in operating activities-96-103-40
Capital expenditures--1-2
Payments to Acquire Investments43-44
Sales and maturities of investments1043510
Cash Acquired from Acquisition38--
Net cash used in investing activities9834-36
Proceeds from equity offerings2730-
Payments of Stock Issuance Costs0--
Proceeds from issuance of debt-146-
Repayments of Long-term Debt-43-
Payments of debt issuance costs-5-
Payments for loss on extinguishment of debt-1-
Proceeds from Stock Plans111
Proceeds from Stock Options Exercised000
Repurchase of common stock withheld for taxes101
Net cash provided by financing activities27127-0
Increase (decrease) in cash and cash equivalents-59-76
Cash paid for interest71115
Issuance Of Warrants For Loan Agreement-2-
Initial operating lease right-of-use assets for adoption of ASU 2016-02-6-
Operating Lease Liabilities Incurred During Period-14-
Stock issued in connection with the Acquisition138--
Noncash Or Part Noncash Acquisition, Equity Assumed9--
Noncash or Part Noncash Acquisition, Debt Assumed23--